Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Jin, NJ
Chaolun Harry Jin, West Windsor, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080228661 | SYSTEMS AND METHODS FOR PROVIDING FINANCIAL SERVICES - A new method and system for providing financial services is provided. These methods and systems can include providing banking and investment services to hedge fund money managers and other customers without the assistance or need for a prime broker. While employing the present invention a money manager may receive prime brokerage services from a bank or other financial service while at the same time be able to pursue investment opportunities with this bank or financial institution and other banks, institutions, and brokerages. The prime brokerage services that a money manger may receive can include accounting services, loan services, and cash management. | 09-18-2008 |
| 20080281751 | COLLATERAL REQUIREMENTS MATCHING AND DISPUTE RESOLUTION - A collateral management method for a plurality of parties, each of the parties having a collateral requirement with at least one other party of the plurality of parties is disclosed, the method including matching the collateral requirements of the plurality of parties to determine a net collateral requirement of a party of the plurality of parties to one or more other parties of the plurality of parties, and making available for that party the net collateral requirement of that party. | 11-13-2008 |
Haihong Jin, Manalapan, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090286817 | 4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds and Methods of Their Use - Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders: | 11-19-2009 |
| 20100087433 | Methods of inhibiting tryptophan hydroxylase - Compounds, compositions and methods of treating serotonin-mediated diseases and disorders are disclosed. | 04-08-2010 |
| 20100280054 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE - Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders: | 11-04-2010 |
Jiaqi Jin, Harrison, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090132336 | Online Advertiser Acquisition And Valuation - A method for valuating an advertiser considered for acquisition includes capturing click-related data by users with reference to a plurality of advertisements owned by a plurality of advertisers in a keyword market; calculating a marginal value of each of the plurality of advertisers as a function of a plurality of averaged market factors, wherein the marginal value of an additional advertiser is also calculated to result in at least an estimated displaced revenue if at least one advertisement of the additional advertiser for at least one keyword were competitively included in the keyword market; and deciding whether to pursue the additional advertiser based on the marginal value of the additional advertiser as associated with the at least one keyword. | 05-21-2009 |
| 20090132340 | Advertisement Display Depth Optimization - A method for maximizing page yield in advertisement display to Web users includes tracking click activity associated with advertisements displayed to users through a hierarchal set of search results pages associated with a keyword; tracking bidding activity by advertisers related to the keyword and corresponding advertisements of the advertisements; applying at least one component model to the click or bidding activity as correlated with a particular search results page of the hierarchal set of search results pages via which the advertisements receiving the click activity are displayed, wherein the at least one component model generates a set of output values representative of the tracked click activity; and providing the output values to the at least one component model to iteratively optimize a number of advertisements displayed on the particular search results page via which at least some of the advertisements are displayed in response to a query for the keyword. | 05-21-2009 |
Keye G. Jin, Montclair, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110246368 | METHOD AND APPARATUS FOR A NO PRE-SET SPENDING LIMIT TRANSACTION CARD - A method and apparatus are provided for a no pre-set spending limit transaction card with features and attributes of both a credit card and a charge card, including an overlimit spend feature and an associated communicated line of credit. The transaction card may carry a balance like a credit card and may require that a card user pay down the balance carried forward to the line of credit subsequent to the end of each billing cycle. When the user has reached or exceeded the communicated line of credit, each subsequent transaction request for a new transaction by the user is evaluated on a case-by-case basis by a process that includes execution an overlimit spend authorization logic or process | 10-06-2011 |
Richard Jin, Pennington, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20100041599 | Compositions and methods for bone formation, bone remodeling and toxin protection - The present invention identifies compounds that disrupt the interaction between anthrax proteins and LRP5/6 receptors, resulting in a reduction in anthrax toxicity. The compounds act to disrupt the intracellular transport of toxin complexes into a target cell. The present invention also provides methods for testing the effect of compounds on Wnt activity, through the use of in vitro experiments involving cells that have in at least one gene mutation involved in the Wnt pathway. | 02-18-2010 |
| 20100298200 | Compounds and assays for controlling Wnt activity - The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions. | 11-25-2010 |
| 20110105606 | Compositions and methods affecting the signaling pathways of LRP receptors - The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands. | 05-05-2011 |
Shengkan Jin, Belle Mead, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110244059 | INHIBITING OBESITY PROGRESSION BY INHIBITING ADIPOCYTE DIFFERENTIATION WITH A PRE-ADIPOCYTE AUTOPHAGY INHIBITOR - The present invention relates to methods of mitigating, preventing or treating weight gain or obesity in patients by administering one or more autophagy inhibitors, thereby, preventing the differentiation process of pre-adipocyte cells into a mature adipocytes. Specifically, the present invention relates to the surprising discovery that autophagy is critical for the cellular remodeling required during pre-adipocyte differentiation into mature adipocyte. By targeting and inhibiting one or more mechanisms in autophagy, adipocyte maturation is also inhibited, thus, providing a novel a pathway to prevent, mitigate and/or treat weight gain, obesity and associated diseases, such as type II diabetes. | 10-06-2011 |
Tuo Jin, Highland Park, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080248098 | Polysaccharide Microparticles Containing Biological Agents: Their Preparation and Applications - A method of preparing polysaccharide glassy microparticles which are less than 10 μum in diameter and contain structurally delicate agents, such as proteins, peptides, gene materials, vaccines, antibodies, viruses and liposomes using low-temperature aqueous-aqueous emulsification (free of polyelectrolytes) and freezing-induced phase separation. When delicate agents are added to a polysaccharide-PEG two phase system followed by homogenization (or other shear adding process), the agents partition into the polysaccharide dispersed phase preferentially. These processes help to avoid aggregation of proteins caused by interaction with charged polyelectrolytes used for stabilizing the polysaccharide dispersed phase in our previously reported aqueous-aqueous emulsion. When this system is frozen and lyophilized, glassy particles less than 10 μm in diameter containing delicate agents can be formed. These fine polysaccharide particles protect proteins within their hydrophilic glassy matrix, and can therefore be easily suspended in hydrophobic polymer solutions and formulated to various forms of sustained release devices such microsphere, sheets, fibers, coating layers, and scaffolds. The particles can also be dispersed in hydrophilic gels to improve releasing kinetics and to deliver vaccines and antibodies for immune therapy. | 10-09-2008 |
| 20090028904 | Novel cochleate formulations - A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca | 01-29-2009 |
| 20090036417 | COCHLEATES WITHOUT METAL CATIONS AS BRIDGING AGENTS - This invention provides a cochleate and nano-cochleate systems wherein the agents bridging lipid bilayer are organic multi-valent cations. This invention also provides a method for preparing the cochleate system comprising direct cochleation and hydrogel-isolated procedure. The preparation method comprises using the charge ration between the bridging agents and lipids to control the particle sizes. This cochleate or nano-cochleate system may be used for microencapsulation and delivery of therapeutics wherein the therapeutic agents are loaded in the cochleate structure as the bridging agents between lipid bilayers. Finally, this invention provides other uses of these new cochleate and nano- cochleate systems. | 02-05-2009 |
| 20110076307 | POLYCATIONIC GENE CARRIERS FORMED OF ENDOGENOUS AMINO GROUP-BEARING MONOMERS - The present invention is directed to a design of and a method to synthesize polycations for gene (DNA and RNA) delivery. According to this design, the polycations (also said cationic polymers) are formed by polymerization of endogenous monomers bearing sufficient amino groups through degradable bonds with linker molecules or with themselves. The amino group-bearing monomers are those naturally existing in or nontoxic to human body. The linker molecules are those which are not only degradable to nontoxic fragments but also able to release the amino group-bearing monomers in their native state upon degradation. Some examples for the endogenous amino group-bearing monomers are spermine, spermidine, serine or N,N-dimethyl serine, and histidine. Examples for the degradable chemical bonds formed between the amino group-bearing monomers are carbamate, imine, amide, carbonate, and ester. In order to improve degradability or proton sponging effect, low pKa (<8) amino group(s) or other electron donating group(s) is incorporated in the linker between the two (or three) reactive groups for linking the amino group-bearing monomers. These polycationic carrier systems can be used for nano-encapsulation and transfection of gene materials. | 03-31-2011 |
Weihong Jin, Fanwood, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20100190231 | METHODS FOR CRYSTALLIZING ERK2 POLYPEPTIDES - The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design. | 07-29-2010 |
Yinsheng Jin, Princeton, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20080317738 | Mylks as Modifiers of Branching Morphogenesis and Methods of Use - Human MYLK genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MYLK are provided. | 12-25-2008 |
Yun Jin, Morristown, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20110208128 | Safety Drug Delivery Connectors - Drug delivery connectors are provided for permitting and blocking fluid flow between a container and a catheter connector or other drug delivery site. Embodiments of the drug delivery connectors include a ball valve for forming a releasable seal within the drug delivery connectors. In one or more embodiments, the ball valve prevents fluid flow between an open proximal end and an open distal end of the drug delivery connector and is movable in a proximal direction to release the releasable seal to permit fluid flow from the open proximal direction to the open distal direction. Methods of delivering medication to a catheter connector that includes an actuator are also provided | 08-25-2011 |
| 20110208160 | Safety Drug Delivery System - Drug delivery systems are provided that include an actuator assembly permanently attached to a filter for connection of a container containing medications such as epidural anesthesia, to a delivery site. In one or more embodiments, the actuator assembly includes a projection with an opening extending from a distal end of the actuator assembly in a proximal direction and the filter includes an inlet and an outlet in fluid communication with the opening. The filter includes a housing including two plates joined together or a cylindrical body defining a cavity containing filter materials. A conduit may be attached to the outlet of the filter to allow connection of the drug delivery systems described to a delivery site, such as a catheter. Methods of administering a medication to a delivery site are also provided. | 08-25-2011 |